Fixed-dose combinations containing stavudine have played a critical role in the worldwide scale-up of antiretroviral therapy, but increasing concern exists regarding adverse events due to mitochondrial toxicity. We describe the first reported occurrence of lactic acidosis within a family of 3 HIV-infected individuals. This report is only the second of lactic acidosis affecting an African child. Further research is indicated to identify possible genetic and other risk factors underlying mitochondrial toxicity in African populations, especially among pediatric cohorts.
World Health Organization/UNAIDS/UNICEF.Towards Universal Access: scaling Up Priority HIV/AIDS Interventions in the Health Sector: progress Report 2009. World Health Organization; Geneva, Switzerland: World Health Organization; 2009.
2.
Boulle A., Orrel C., Kaplan R., et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort . Antivir Ther. 2007;12(5):753-760.
3.
van Griensven J., De Naeyer L., Mushi T., et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg. 2007;101(8):793-798.
4.
Bolhaar MG, Karstaedt ASA high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa . Clin Infect Dis. 2007;45(2):254-260.
5.
World Health Organization: Rapid Advice.Antiretroviral Therapy for HIV Infection in Adults and Adolescents. World Health Organization; Geneva, Switzerland: World Health Organization; 2009.
6.
Van Dyke RB, Wang L., Williams PLToxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. J Infect Dis. 2008;198(11):1599-1608.
7.
Noguera A., Fortuny C., Sanchez E., et al. Hyperlactatemia in human immunodeficiency virus-infected children receiving antiretroviral treatment. Pediatr Infect Dis J. 2003;22(9): 778-782.
8.
Desai N., Mathur M., Weedon J.Lactate levels in children with HIV/AIDS on highly active antiretroviral therapy . AIDS. 2003; 17(10):1565-1568.
9.
Aldrovandi GM , Lindsey JC, Jacobson DL, et al. Morphologic and metabolic abnormalities in vertically HIV-infected children and youth . AIDS.2009;23(6):661-672.
10.
Alves C., Oliveira AC, Brites C.Lipodystrophic syndrome in children and adolescents infected with the human immunodeficiency virus. Braz J Infect Dis. 2008;12(4):342-348.
11.
Aurpibul L. , Puthanakit T., Lee B., Mangklabruks A., Sirisanthana T., Sirisanthana V.Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Antivir Ther. 2007;12(8): 1247-1254.
12.
Parakh A., Dubey AP, Kumar A., Maheshwari A.Lipodystrophy and metabolic complications of highly active antiretroviral therapy. Indian J Pediatr.2009;76(10):1017-1021.
13.
Kabue MM, Buck WC, Kazembe PN, Kline MWDiscontinuation of standard first-line antiretroviral therapy in a cohort of 1434 Malawian children. 5th International AIDS Society Conference on HIV Pathogenesis and Treatment, WEPED175, Capetown, South Africa; July 19-22, 2009.
14.
Hawkins C., Achenbach C., Fryda W., Ngare D., Murphy R.Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr. 2007; 45(3):304-310.
15.
Westreich DJ , Sanne I., Maskew M., et al. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis.2009;48(11):1617-1623.
16.
Yamanaka H. , Gatanaga H., Kosalaraksa P., et al. Novel mutation of human DNA polymerase gamma associated with mitochondrial toxicity induced by anti-HIV treatment . J Infect Dis. 2007 ; 195(10):1419-1425.
17.
Affandi JS, Price P., Imran D., Yunihastuti E., Djauzi S., Cherry CLCan we predict neuropathy risk before stavudine prescription in a resource-limited setting? AIDS Res Hum Retroviruses. 2008; 24(10):1281-1284.
18.
Oyugi JH, Byakika-Tusiime J., Ragland K., et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda . AIDS. 2007;21(8):965-971.
Church JA, Mitchell WG, Gonzalez-Gomez I., et al. Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver failure in an HIV-infected child treated with combination antiretroviral therapy. J Pediatr. 2001;138(5):748-751.
21.
UNAIDS: AIDS Epidemic Update.Joint United Nations Program on HIV/AIDS (UNAIDS) and World Health Organization ; 2007.
